RxDoctor Payments Data

Sanjum Sethi, MD

Interventional Cardiology · New York, NYNPI 1174783336

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $148,855 of the $232,474 with a category attached, or 64.0%. 34 manufacturers reported payments, led by Johnson & Johnson at 43.6% of the total. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$232,474in general payments, 2019–2025

Across 544 payments — averaging $427.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$101K
  • Boston Scientific$74K
  • Terumo Medical Corporation$12K
  • Chiesi USA, Inc.$11K
  • Angiodynamics, Inc.$10K
  • Inari Medical, Inc.$7K
  • plus $16K from 28 others
$368,007in research payments, 2019–2025

Across 173 payments — averaging $2127.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Penumbra, Inc.$130K
  • Inari Medical, Inc.$100K
  • Terumo Medical Corporation$64K
  • Boston Scientific$61K
  • Angiodynamics, Inc.$13K

What the payments were for

  • Consulting fees$34,77815%
  • Speaking & faculty fees$148,85564%
  • Travel & lodging$23,52810%
  • Food & beverage$25,27511%
  • Education$380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$232,474 in reported general payments places this provider in the 90th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$121,023
Medicare patients
258
Services billed
811

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$97,599
XareltoRivaroxaban50$50,764
EntrestoSacubitril/Valsartan23$22,058
Metoprolol Succinate61$965
Rosuvastatin Calcium29$777
Atorvastatin Calcium61$692
Ranolazine ErRanolazine11$488
ClopidogrelClopidogrel Bisulfate30$342
Pregabalin17$228
Amlodipine Besylate42$221
Furosemide31$212
Carvedilol21$206
Losartan Potassium17$170
Lisinopril23$150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$97,59995 claims
Johnson & JohnsonXarelto$101,372$50,76450 claims
NovartisEntresto$451$22,05823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →